Pacira BioSciences: Exparel Still Supports My Original Bull Case
Pacira BioSciences continues to rely heavily on its product Exparel, which is central to its business model. The company is expected to face significant catalysts in 2026, particularly regarding its pipeline readouts. However, the reliance on Exparel raises concerns about potential risks associated with patents and reimbursement policies.
- ▪Pacira BioSciences is focused on non-opioid pain management products, including Exparel, Zilretta, and Iovera.
- ▪The company is anticipating important pipeline readouts in 2026 that could impact its stock performance.
- ▪There are concerns regarding Pacira's overdependence on Exparel and the associated risks in the biotech sector.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906276-pacira-biosciences-stock-exparel-still-supports-my-original-bull-case"},"author":{"@type":"Person","name":"Myriam…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
